A single arm, prospective, open-label, pilot study to assess effects of the switch from sirolimus to everolimus in stable maintenance renal transplant patients receiving a calcineurin inhibitor free regimen.

Trial Profile

A single arm, prospective, open-label, pilot study to assess effects of the switch from sirolimus to everolimus in stable maintenance renal transplant patients receiving a calcineurin inhibitor free regimen.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Nov 2011 Actual end date (Mar 2006) added as reported by ClinicalTrials.gov.
    • 14 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top